BIO vs. KYMR: Bio-Rad Laboratories vs. Kymera Therapeutics Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while KYMR is classified in Biotechnology.

Bio-Rad Laboratories (BIO) has more than two decades of public-market history since February 27, 1980, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO) reports 14.27%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) at 39.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Bio-Rad Laboratories (BIO) reports 11.82%, ranking against industry peers normally.

Profitability Metrics

Growth

Bio-Rad Laboratories (BIO) at 0.65% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither Bio-Rad Laboratories (BIO) nor Kymera Therapeutics (KYMR) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Bio-Rad Laboratories (BIO) at 3.18 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Bio-Rad Laboratories (BIO) at 0.18 and Kymera Therapeutics (KYMR) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Bio-Rad Laboratories (BIO) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Bio-Rad Laboratories (BIO) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO) trades at 10.14 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Kymera Therapeutics (KYMR) at 6.96 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics